Sunshine Biopharma seeks global market through new Canadian subsidiary
- Quebec-based Sunshine Biopharma has formed Sunshine Biopharma Canada to manufacture, market, sell and distribute contracts for various pharmaceutical products .
- Sunshine Biopharma focuses on developing and commercializing treatments for metastatic and multidrug-resistant cancers.
- The company is attempting to generate revenue in the near term as it continues development of its flagship cancer drug, Adva-27a.
The global generics market is estimated to be worth more than $100 billion. According to Sunshine Biopharma’s CEO, Dr. Steve Slilatig, launching the new subsidiary will allow the company to generate revenues in the near term while positioning itself to market and distribute Adva-27a, a small molecule drug that is just entering phase I development as a treatment for multidrug-resistant breast cancer, small-cell lung cancers, uterine sarcoma cells and pancreatic cancer cells.